Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for MacroGenics, Inc. (MGNX : NSDQ)
 
 • Company Description   
MacroGenics Inc. is a biopharmaceutical company. It is focused on discovering and developing innovative monoclonal antibody-based therapeutics. The Company has a diverse portfolio of product candidates focused in three therapeutic areas: oncology, autoimmune disorders and infectious diseases. MacroGenics Inc. is headquartered in Rockville, Maryland.

Number of Employees: 427

 
 • Price / Volume Information   
Yesterday's Closing Price: $4.31 Daily Weekly Monthly
20 Day Moving Average: 927,548 shares
Shares Outstanding: 61.33 (millions)
Market Capitalization: $264.35 (millions)
Beta: 2.13
52 Week High: $32.81
52 Week Low: $3.92
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -47.57% -42.78%
12 Week -57.54% -55.29%
Year To Date -73.15% -68.70%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
9704 MEDICAL CENTER DRIVE
-
Rockville,MD 20850
USA
ph: 301-251-5172
fax: 301-251-5321
None http://www.macrogenics.com
 
 • General Corporate Information   
Officers
Scott Koenig - Chief Executive Officer;President and Director
James Karrels - Senior Vice President; Chief Financial Officer and
Lynn Cilinski - Vice President; Controller and Treasurer
Paulo Costa - Director
Karen Ferrante - Director

Peer Information
MacroGenics, Inc. (BJCT)
MacroGenics, Inc. (CADMQ)
MacroGenics, Inc. (APNO)
MacroGenics, Inc. (UPDC)
MacroGenics, Inc. (IMTIQ)
MacroGenics, Inc. (CYGN)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED PRODUCTS
Sector: Medical
CUSIP: 556099109
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 08/04/22
Share - Related Items
Shares Outstanding: 61.33
Most Recent Split Date: (:1)
Beta: 2.13
Market Capitalization: $264.35 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.96 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-3.15 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 4.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/04/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 1.48
Price/Cash Flow: -
Price / Sales: 3.69
EPS Growth
vs. Year Ago Period: -20.00%
vs. Previous Quarter: -13.68%
Sales Growth
vs. Year Ago Period: -34.24%
vs. Previous Quarter: -21.53%
ROE
03/31/22 - -84.52
12/31/21 - -67.34
09/30/21 - -46.52
ROA
03/31/22 - -61.00
12/31/21 - -50.89
09/30/21 - -35.82
Current Ratio
03/31/22 - 3.25
12/31/21 - 3.75
09/30/21 - 4.86
Quick Ratio
03/31/22 - 3.18
12/31/21 - 3.69
09/30/21 - 4.80
Operating Margin
03/31/22 - -303.19
12/31/21 - -260.97
09/30/21 - -126.03
Net Margin
03/31/22 - -303.19
12/31/21 - -260.97
09/30/21 - -126.03
Pre-Tax Margin
03/31/22 - -303.19
12/31/21 - -260.97
09/30/21 - -126.03
Book Value
03/31/22 - 2.91
12/31/21 - 3.91
09/30/21 - 4.76
Inventory Turnover
03/31/22 - 0.55
12/31/21 - 0.50
09/30/21 - 0.41
Debt-to-Equity
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - 0.00
Debt-to-Capital
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - 0.00
 

Powered by Zacks Investment Research ©